A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients.

Trial Profile

A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs GSK 256066 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 May 2010 Results presented at 106th International Conference of the American Thoracic Society.
    • 01 May 2009 Actual patient number (104) added as reported by ClinicalTrials.gov.
    • 01 May 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top